Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down – Here’s What Happened

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares gapped down prior to trading on Wednesday . The stock had previously closed at $39.75, but opened at $32.72. Supernus Pharmaceuticals shares last traded at $34.98, with a volume of 255,949 shares changing hands.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $57.00 to $36.00 in a report on Wednesday.

Supernus Pharmaceuticals Trading Down 4.5 %

The company has a market cap of $1.83 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90. The company has a fifty day moving average price of $37.55 and a two-hundred day moving average price of $35.27.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.30% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 352 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Supernus Pharmaceuticals by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,599 shares of the specialty pharmaceutical company’s stock valued at $330,000 after buying an additional 4,140 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Rice Hall James & Associates LLC now owns 540,788 shares of the specialty pharmaceutical company’s stock valued at $16,862,000 after buying an additional 38,202 shares in the last quarter. Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares in the last quarter. Finally, James Investment Research Inc. boosted its stake in Supernus Pharmaceuticals by 39.8% in the 3rd quarter. James Investment Research Inc. now owns 17,644 shares of the specialty pharmaceutical company’s stock valued at $550,000 after buying an additional 5,022 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.